Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrigAMI-2: Amivantamab vs Cetuximab in First-line Left-sided Colorectal Cancer
NCT06662786Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of amivantamab in colorectal cancer (CRC), sponsored by Janssen Pharmaceutical. Started Oct 2024; status: recruiting.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06662786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662786.